Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YH 14618

Next Previous
Drug Profile

YH 14618

Alternative Names: P2K; Peniel 2K; Peniel-2000; YH14618

Latest Information Update: 03 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ensol Biosciences
  • Developer Yuhan
  • Class Peptides
  • Mechanism of Action Transforming growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 06 Sep 2017 YH 14617 is still in phase II development for Intervertebral disc degeneration in South Korea (Yuhan Corporation pipeline, September 2017)
  • 01 Aug 2016 Yuhan Corporation completes a phase IIb trial for Intervertebral disc degeneration in South Korea (NCT02320019)
  • 01 Mar 2015 Phase-II clinical trials in Intervertebral disc degeneration in South Korea (Intra-articular) (NCT02320019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top